Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1,538 out of 166,615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 52,913 | 53,749 |
| Total Cites | 26,686 | 30,794 |
| H-index | 87 | 93 |
| Hm-index | 24 | 26 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 18 | 19 |
| Number of Single+First Authored Papers | 19 | 19 |
| Total Cites to Single+First Authored Papers | 1,022 | 1,123 |
| Number of Single+First+Last Authored Papers | 115 | 115 |
| Total Cites to Single+First+Last Authored Papers | 8,236 | 9,485 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 21,659 | 23,734 |
| Ratio of Total Citations to Distinct Citing Papers | 1.23 | 1.30 |
| Self-Citation Percentage |
13.34%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1,496 out of 157,372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 50,647 | 51,647 |
| Total Cites | 25,483 | 29,500 |
| H-index | 85 | 92 |
| Hm-index | 24 | 25 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 18 | 19 |
| Number of Single+First Authored Papers | 19 | 19 |
| Total Cites to Single+First Authored Papers | 1,002 | 1,104 |
| Number of Single+First+Last Authored Papers | 113 | 113 |
| Total Cites to Single+First+Last Authored Papers | 7,909 | 9,136 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 20,625 | 22,649 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.30 |
| Self-Citation Percentage |
13.62%
|
|
Cerundolo, Vincenzo
MRC Weatherall Institute of Molecular Medicine,
United Kingdom
2023 Rank: 47,390
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1,430 out of 147,556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 47,390 | 48,581 |
| Total Cites | 24,341 | 28,252 |
| H-index | 84 | 91 |
| Hm-index | 23 | 25 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 18 | 19 |
| Number of Single+First Authored Papers | 19 | 19 |
| Total Cites to Single+First Authored Papers | 987 | 1,089 |
| Number of Single+First+Last Authored Papers | 112 | 112 |
| Total Cites to Single+First+Last Authored Papers | 7,594 | 8,800 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 19,618 | 21,582 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.31 |
| Self-Citation Percentage |
13.84%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1,399 out of 138,599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 44,427 | 45,578 |
| Total Cites | 22,996 | 26,796 |
| H-index | 82 | 87 |
| Hm-index | 23 | 24 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 18 | 19 |
| Number of Single+First Authored Papers | 19 | 19 |
| Total Cites to Single+First Authored Papers | 967 | 1,068 |
| Number of Single+First+Last Authored Papers | 111 | 111 |
| Total Cites to Single+First+Last Authored Papers | 7,228 | 8,407 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 18,438 | 20,331 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.32 |
| Self-Citation Percentage |
14.18%
|
|
Cerundolo, Vincenzo
University of Oxford Medical Sciences Division,
United Kingdom
2021 Rank: 43,424
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1,373 out of 127,911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 43,424 | 43,643 |
| Total Cites | 22,076 | 25,787 |
| H-index | 80 | 87 |
| Hm-index | 22 | 24 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 18 | 19 |
| Number of Single+First Authored Papers | 19 | 19 |
| Total Cites to Single+First Authored Papers | 956 | 1,057 |
| Number of Single+First+Last Authored Papers | 109 | 109 |
| Total Cites to Single+First+Last Authored Papers | 7,025 | 8,189 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 17,635 | 19,468 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.32 |
| Self-Citation Percentage |
14.39%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1,278 out of 108,509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 39,727 | 40,860 |
| Total Cites | 20,400 | 23,879 |
| H-index | 80 | 85 |
| Hm-index | 21 | 23 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 18 | 19 |
| Number of Single+First Authored Papers | 19 | 19 |
| Total Cites to Single+First Authored Papers | 934 | 1,030 |
| Number of Single+First+Last Authored Papers | 106 | 106 |
| Total Cites to Single+First+Last Authored Papers | 6,522 | 7,614 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 16,188 | 17,890 |
| Ratio of Total Citations to Distinct Citing Papers | 1.26 | 1.33 |
| Self-Citation Percentage |
14.57%
|
|
Trending Researchers
.jpeg)
Top 2% Scientists by Country
United Kingdom18,125 scientists, 3rd in the world
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.